Jill Krapf MD

Jill Krapf MD I am a board-certified OB/GYN who specializes in v***ar disorders and s*xual pain.

New study recruiting now!The NEW study on topical ketotifen for provoked vestibulodynia (pain at the v@ginal entrance wi...
02/25/2026

New study recruiting now!

The NEW study on topical ketotifen for provoked vestibulodynia (pain at the v@ginal entrance with touch- entry pain with insertion) was presented at the ISSWSH annual meeting.

Now recruiting for the following study sites:

Tampa, FL
Washington, DC
New York, NY

Involves 4 in-person visits. Contact research.cvvd@gmail.com if you are interested in participating.

New study recruiting now!This is the protocol for the NEW study on topical ketotifen for provoked vestibulodynia (pain a...
02/24/2026

New study recruiting now!

This is the protocol for the NEW study on topical ketotifen for provoked vestibulodynia (pain at the v@ginal entrance with touch- entry pain with insertion) which was presented resented at the ISSWSH annual meeting.

Now recruiting for the following study sites:

Tampa, FL
Washington, DC
New York, NY

Involves 4 in-person visits. Contact research1.cvvd@gmail.com if you are interested in participating.

LAST CHANCE!!Recruitment is ending for the Strata Trial for so we are doing a final call for anyone who would like to ...
02/23/2026

LAST CHANCE!!

Recruitment is ending for the Strata Trial for so we are doing a final call for anyone who would like to participate.

This is a clinical research study evaluating a silicone-based gel called StrataMGT for reducing symptoms such as itching, burning, soreness, and pain with in*******se.

What is being studied?
StrataMGT is a topical silicone-based gel designed to form a protective, breathable barrier over the skin. The goal of the study is to determine whether it improves symptoms and visible inflammation in v***ar lichen sclerosus.

Study Details
• Participation lasts 14 weeks

• Participants are randomly assigned (50/50) to receive either StrataMGT or an inactive placebo gel

• Neither participants nor investigators will know which group someone is in during the study

• Up to 100 participants will be enrolled

What’s involved?
• Questionnaires about itching, burning, soreness, and pain

• Vulvar exams at study visits

• A vaginal culture at screening

• Photographs of the v***a at the beginning and end of the study to assess inflammation

• Application of the study gel as directed

• NO BIOPSIES REQUIRED

Participants must remain on their stable steroid or calcineurin inhibitor regimen during the study.

Risks
The main known risk is local skin irritation. As with any study, not all risks are known.

Compensation
Participants receive $100 per completed in-clinic visit to help cover travel and parking expenses.

Study Locations
• The Centers for Vulvovaginal Disorders – New York, NY
Washington, DC
Tampa, FL
• University of Utah

Participation is completely voluntary, and you may withdraw at any time.

If you’re interested in learning more or seeing if you qualify, please contact: research.cvvd@gmail.com

Lichen sclerosus remains under-researched, and carefully conducted clinical trials are essential to improving treatment options. Whether or not you choose to participate, increasing awareness helps move the field forward. FEEL FREE TO POST ON SUPPORT GROUPS, MESSAGE BOARDS, and SHARE!!

Research presented at showing surgical management of scarring related to improves function and distress. Largest dat...
02/18/2026

Research presented at showing surgical management of scarring related to improves function and distress. Largest data set of 86 LS patients undergoing scar release surgery with and over the span of 22 years showing 93% overall satisfaction, 86% increased sensation of at least 75%, 92% increased org@sm function, and 90% improved pain with insertion. Clinically meaningful recurrence rate below average in literature at 10%. Life-changing for patients to restore function. So grateful to present these results. Manuscript currently under peer review and hope it will be published soon!

🚨 alert 🚨 Hot off the press!!! The and just announced the first updated labels. These are the first companies to agre...
02/12/2026

🚨 alert 🚨

Hot off the press!!!

The and just announced the first updated labels. These are the first companies to agree to language.

Check out the press release and details.

https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information

The most magical update: NO BOXED LABELING ON VAGINAL HORMONE THERAPY!!!

Vaginal Hormones:
- prevent urinary tract infections, sepsis and death
- fix urinary frequency, urgency, and leakage
- they help lubrication, pain with s*x and satisfaction
- they have NEVER been shown to cause cancer of any kind or blood clots

As of 2025 there are now guidelines in place to teach out how and why

Free training and guide to teach you how
https://www.rachelrubinmd.com/education

Read the new Guidelines here: https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopause

Women and girls in science help make the world better 💙Their discoveries have saved lives ❤️‍🩹, advanced medicine 💊, pr...
02/12/2026

Women and girls in science help make the world better 💙

Their discoveries have saved lives ❤️‍🩹, advanced medicine 💊, protected our planet 🌎, and expanded what’s possible for humanity 🌐

On the International Day of Women and Girls in Science, let’s ensure every mind has the chance to shape a shared future .

“The current treatment of provoked vestibulodynia involving neuroproliferation is often complete vestibulectomy; howeve...
01/26/2026

“The current treatment of provoked vestibulodynia involving neuroproliferation is often complete vestibulectomy; however, less invasive treatments are biologically plausible, yet lack study. The International Society for the Study of Women’s Sexual Health, the National Vulvodynia Association, the Gynecologic Cancers Research Foundation, and Tight Lipped, a grassroots nonprofit organization that supports people with chronic vulvovaginal and pelvic pain, collectively sponsored a conference, the Vulvodynia Therapeutic Research Summit, held in April 2024.

The primary objective of the Vulvodynia Therapeutic Research Summit was to identify options for further research of the treatment of provoked vestibulodynia through expert consensus.

This executive summary describes the rationale for identifying specific pharmacologic agents and medical devices as targets for research directed toward treatment of the neuroinflammatory process found in the vestibular mucosa of provoked vestibulodynia.”

Read the full summary at GreenJournal.org or in this month’s issue (link in profile )

LS Awareness Day is tomorrow, and we would love to have you with us. If you’ve been feeling overwhelmed by your diagnos...
01/16/2026

LS Awareness Day is tomorrow, and we would love to have you with us. If you’ve been feeling overwhelmed by your diagnosis or lost in the “medical talk,” this event was created just for you.

What to expect: 🎬 2:00 PM EST: A live screening of Dr. Jill Krapf’s masterclass. 💬 Live Chat: Our founder, Kathy Ruiz-Carter, will be right there in the chat to address myths and support your questions in real-time. 🙋‍♀️ Live Q&A: A full hour with Dr. Jill Krapf to get into the “how” and “why” of LS care.

Cost: Completely Free (thanks to our amazing donors!). Replay: Can’t make it live? Register anyway, and we’ll email the replay to you on Jan 19.

If you know someone else who is struggling in silence, please share this link. One share can change someone’s entire outlook on their health.

👉 Register or share here: lssupportnetwork.org/lsa
Comment “LSA” for a link sent to your inbox

Great day in the OR… restoring anatomy and function for those with and . Will be presenting an exciting study on lon...
01/16/2026

Great day in the OR… restoring anatomy and function for those with and . Will be presenting an exciting study on long-term outcomes of lysis of v***ar adhesions (scar release surgery) in patients with LS on s*xual function and patient satisfaction at the upcoming ISSWSH meeting in February. The study was also submitted for peer review to a major OB/Gyn journal, so hoping we can share this amazing data soon.

Are you a patient with LS suffering from pain with insertion or decreased function? There is so much we can do! Contact the Center for Vulvovaginal Disorders Florida at appointments@jillkrapfmd for more information.

Honored to be educating with this fabulous group at the ISSWSH Fall Course *xmedpa
11/15/2025

Honored to be educating with this fabulous group at the ISSWSH Fall Course





*xmedpa




Address

3216 W Azeele Street
Tampa, FL
33609

Opening Hours

Tuesday 9am - 1pm
Wednesday 9am - 1pm
Thursday 9am - 1pm

Telephone

+18133587634

Website

Alerts

Be the first to know and let us send you an email when Jill Krapf MD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Jill Krapf MD:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Bio

Dr. Jill Krapf graduated from Lafayette College and then earned an M.D. from Jefferson Medical College in Philadelphia, Pennsylvania. She completed a residency in Obstetrics and Gynecology at The George Washington University, serving as Chief Administrative Resident in her final year. After residency, Dr. Krapf completed a Medical Education fellowship and subsequently earned a Masters in Education. Dr. Krapf is board certified by the American Board of Obstetrics and Gynecology and has been active in leadership roles and committees in the American College of Obstetricians and Gynecologists (ACOG) and the Association of Professors of Gynecology and Obstetrics (APGO). She practiced at The George Washington University from 2011-2015, starting a clinic specializing in female s*xual health and serving as the Assistant Clerkship Director for Obstetrics and Gynecology. Dr. Krapf then relocated to Texas with her military husband, working as an OB/GYN hospitalist before joining the faculty at University of Texas Health San Antonio. Dr. Krapf is active in research and has published chapters and peer-reviewed articles on vulvodynia, v***ar dermatoses, and hypoactive s*xual desire disorder. She is Associate Editor for the Journal of Sexual Medicine Online Access, as well as for the textbook Female Sexual Pain Disorders, 2nd Edition. She is active in the International Society for the Study of Women’s Sexual Health (ISSWSH), serving on the Education Committee and the Social Media Committee. Dr. Krapf recently moved back home to the Washington D.C. area and joined Dr. Andrew Goldstein at The Center for Vulvovaginal Disorders to devote her practice to the diagnosis and treatment of v***ar pain. She is currently coordinating an ISSWSH education course on Sexual Pain, to be held in April 2020.